• Explore /
  • Poster
  • / Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.

Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.

Abstract Poster

Authors

null

Ying Cheng

Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China

Ying Cheng , Chunjiao Wu , Lulu Chen , Ying Xin , Liang Zhang , Pinghua PAN , Lin Wu , Juan Li , Yanqiu Zhao , Xingya Li , Jun Zhao , Xiaorong Dong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04638491

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8580)

DOI

10.1200/JCO.2022.40.16_suppl.8580

Abstract #

8580

Poster Bd #

206

Abstract Disclosures

Similar Posters

First Author: Antonio Calles

First Author: Melissa Lynne Johnson

First Author: Jose Manuel Trigo Perez

First Author: Shunji Takahashi